REGISTERED NUMBER: 10000693 (England and Wales)

Unaudited Financial Statements

For The Year Ended 31 August 2025

for

JAJ PHARMA LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

J Pradyuman Jani

Mrs M Jaykumar Jani

S P Soni

SECRETARY:

J Pradyuman Jani

REGISTERED OFFICE:

79 College Road

Harrow

Middlesex

HA1 1BD

REGISTERED NUMBER:

10000693 (England and Wales)

ACCOUNTANTS:

Ayman Tyler Associates

Accountants & Tax Advisers

79 College Road

Harrow

Middlesex

HA1 1BD

FIXED ASSETS

Tangible assets

4

57,388

81,396

Investments

5

3,015,000

-

3,072,388

81,396

CURRENT ASSETS

Debtors

6

13,269,318

16,369,533

Cash at bank

5,590,992

5,675,195

18,860,310

22,044,728

CREDITORS

Amounts falling due within one year

7

61,148

240,206

NET CURRENT ASSETS

18,799,162

21,804,522

TOTAL ASSETS LESS CURRENT LIABILITIES

21,871,550

21,885,918

CREDITORS

Amounts falling due after more than one year

8

72,513

85,524

NET ASSETS

21,799,037

21,800,394

CAPITAL AND RESERVES

Called up share capital

10

100

100

Retained earnings

21,798,937

21,800,294

SHAREHOLDERS' FUNDS

21,799,037

21,800,394

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 September 2025 and were signed on its behalf by:

J Pradyuman Jani - Director

1.	STATUTORY INFORMATION

JAJ Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc

-

25% on cost

Investments in associates

Investments in associate undertakings are recognised at cost.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2024 - 3 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 September 2024

108,529

Additions

4,166

At 31 August 2025

112,695

DEPRECIATION

At 1 September 2024

27,133

Charge for year

28,174

At 31 August 2025

55,307

NET BOOK VALUE

At 31 August 2025

57,388

At 31 August 2024

81,396

5.	FIXED ASSET INVESTMENTS

Interest

in

associate

£

COST

Additions

3,015,000

At 31 August 2025

3,015,000

NET BOOK VALUE

At 31 August 2025

3,015,000

On 1st March 2025 the company acquired 125 ordinary shares of £1 each in Arise Pharma Ltd for £3,000,000, representing a 12.5% stake, purchased from an existing shareholder.

6.

DEBTORS

31.8.25

31.8.24

£

£

Amounts falling due within one year:

Other debtors

232,591

230,333

31.8.25

31.8.24

£

£

Amounts falling due after more than one year:

Other debtors

13,036,727

16,139,200

Aggregate amounts

13,269,318

16,369,533

Other debtors balance due within 1 year includes £230,273 loaned to Sapphire Investments Group Ltd.

Other Debtors balance of amounts due more than 1year refers to an amount of £13,036,727 of ascertainable deferred consideration to be received on an earn out basis over 3 years..

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.8.25

31.8.24

£

£

Taxation and social security

10,086

5,585

Other creditors

51,062

234,621

61,148

240,206

8.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.8.25

31.8.24

£

£

Hire purchase contracts (see note 9)

72,513

85,524

9.	LEASING AGREEMENTS

Minimum lease payments under hire purchase fall due as follows:

31.8.25

31.8.24

£

£

Net obligations repayable:

Between one and five years

72,513

85,524

On 19th April 2024 the company entered into a 3 year Hire Purchase agreement, with the option to purchase the asset for £47,675.00 at the end of term.

10.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.8.25

31.8.24

value:

£

£

100

Ordinary

1

100

100

The shareholdings in the company are as follows;

Mansi Jaykumar Jani 72 Ordinary Shares of £1 each

Sanket Pankajkumar Soni 10 Ordinary Shares of £1 each

Krupa Dave 10 Ordinary Shares of £1 each

Khushvi Jani 8 Ordinary Shares of £1 each